UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorpor ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Chris Benecchi - Chief Business Officer Kimi Iguchi - Chief Financial Officer Laura Gault - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Anupam Rama - JPMorgan Ritu Baral - Cowen Eason Lee - Ne ...

Planned activities and anticipated timelines | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|--------------------------|--------------------------|-------| | NDA development and related processes | FDA Advisory Committee* | DEA Scheduling Period^ | | | Medical affairs, health economics, value and access, and commercialization planning | | | | FDA = U.S. Food and Drug Administration; DEA = Drug Enforcement Administration; MDD = major depressive ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-4486580 (State or Other Jurisdictio ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - Chief Executive Officer Kimi Iguchi - Chief Financial Officer Jim Doherty - Chief Development Officer Chris Benecchi - Chief Business Officer Jeff Jonas - Chief Innovation Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Ritu Baral - Cowen Salveen Richter - Goldman Sachs Paul Matteis - Stifel Laura Chico - Wedbush Jay Olson ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of inco ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Helen Rubinstein - IR Barry Greene - CEO Albert Robichaud - Chief Scientific Officer Chris Benecchi - Chief Business Officer Kimi Iguchi - CFO Conference Call Participants Ritu Baral - Cowen Paul Matteis - Stifel Ami Fadia - Needham Jay Olson - Oppenheimer Swapnil Malekar - Piper Sandler Yatin Suneja - Guggenheim Marc Goodman - SVB Leerink Gospel Enyindah-Asonye - Morgan Stanley Gary Nachman ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporati ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Helen Rubinstein - Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Kimi Iguchi - Chief Financial Officer Chris Benecchi - Chief Commercial Officer Conference Call Participants Laura Chico - Wedbush Tiffany Sun - JPMorgan Ritu Baral - Cowen Yatin Suneja - Guggenheim Evan Hua - BMO Capital Markets Vamil Divan - Mizuho Neena Bitritto-Garg - Citi S ...

Investor Presentation May 2022 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can,","expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation include statements reg ...